Tag:
South Africa
Latest Headlines
Latest Headlines
South Africa creates list of drugs it will buy only if they are made there
There will be 70 pharmaceutical products, all solid, oral medications, which the government says must be made in manufacturing plants in the country.
S. Africa ratchets up protection for domestic drugmakers
Warning to pharma companies aiming to sell key drugs in South Africa: Only domestic drugmakers need apply.
TB vaccine in South African trials; blueprint will drive development
A new TB vaccine is expected to complete the first advanced clinical trials in South Africa in 2013.
South Africa, Lonza partner on $210 million API facility
South Africa is partnering with Swiss contract manufacturer Lonza on a $210 million API plant in an investment that looks to cut government costs for treating HIV. Lonza will put up 500 million rand,...
Lonza teams with S. Africa on antiretroviral API plant
Swiss drug manufacturer Lonza has allied with the South African government on a new, $210 million plant to produce antiretroviral APIs. The venture, dubbed Ketlaphela, is aimed at reducing...
Pharma's emerging-markets push fuels cargo growth
Over the past several years, some of the biggest stories in pharma have been international. Manufacturing moving to Asia. Outsourcing and partnerships in India. Big investments in China and Russia.
S. Africa mulls state-run pharma to control HIV med costs
South Africa has decided to take HIV drug pricing into its own hands. After years of complaining that the cost of AIDS drugs was too high, the government says it will start a state-run drug company
Merck KGaA aims to expand in Africa, chairman says
Merck KGaA will have a new Africa strategy within six months, Chairman Frank Stangenberg-Haverkamp said in Johannesburg. The company wants to grow in Africa, probably using South Africa as a sales
Big pharma pounces on South Africa
Drugmakers stand at the ready as South Africa pulls out of recession. Ranbaxy Laboratories has opened its second manufacturing plant there, a $30-million facility called the Be-Tabs Pharmaceuticals
AstraZeneca spurs South African operations
AstraZeneca ( NYSE: AZN ) won't be left behind in South Africa, says CEO David Brennan ( photo ), who tells Bloomberg that his company is boosting its presence in that country. "We have been increasing
